Inhibitory effects of curcumin on passive cutaneous anaphylactoid response and compound 48/80-induced mast cell activation

Yun-Ho Choi¹, Guang-Hai Yan¹,², Ok Hee Chai¹,³, Chang Ho Song¹,³
¹Department of Anatomy, Chonbuk National University Medical School, Jeonju, Korea, ²Department of Anatomy and Histology and Embryology, Yanbian University School of Medical Sciences, Jilin, China, ³Institute for Medical Sciences, Chonbuk National University, Jeonju, Korea

Abstract: Mast cells participate in allergies and inflammation by secreting a variety of pro-inflammatory mediators. Curcumin, the active component of turmeric, is a polyphenolic phytochemical with anti-tumor, anti-inflammatory, anti-oxidative, and anti-allergic properties. The effects of curcumin on compound 48/80-induced mast cell activation and passive cutaneous anaphylactoid reactions are unknown. In this report, we investigated the influences of curcumin on the passive cutaneous anaphylactoid response in vivo and compound 48/80-induced mast cell activation in vitro. The mechanism of action was examined by calcium uptake measurements and cAMP assays in mast cells. Curcumin significantly attenuated the mast cell-mediated passive cutaneous anaphylactoid reaction in an animal model. In agreement with this in vivo activity, curcumin suppressed compound 48/80-induced rat peritoneal mast cell (RPMC) degranulation and histamine release from RPMCs. Moreover, compound 48/80-elicited calcium uptake into RPMCs was reduced in a dose-dependent manner by curcumin. Furthermore, curcumin increased the level of intracellular cAMP and significantly inhibited the compound 48/80-induced reduction of cAMP in RPMCs. These results corroborate the finding that curcumin may have anti-allergic activity.

Key words: Mast cell, Anaphylactoid reaction, Curcumin, Histamine, Calcium

Introduction

Mast cells are the primary effector cells involved in an allergic or immediate hypersensitivity response. Activation of mast cells occurs in response to a challenge by a specific antigen against which the surface immunoglobulin E (IgE) is directed, or by other IgE-directed ligands. Activated mast cells can produce histamine, as well as a wide variety of other inflammatory mediators such as eicosanoids, proteoglycans, proteases and several pro-inflammatory and chemotactic cytokines such as tumor necrosis factor-α, interleukin (IL)-6, IL-4, IL-8, and IL-13 (Kalesnikoff & Galli, 2008). Among them, histamine remains the best-characterized and most potent vasoactive mediator implicated in the acute phase of immediate hypersensitivity (Petersen et al., 1996). Various acute and chronic allergic responses are caused by these mediators. Mast cell degranulation can also be elicited by the basic secretagogues. The most potent secretagogues include the synthetic compound 48/80 and polymers of basic amino acids (Ennis et al., 1980). Compared with the natural process, a high concentration of compound 48/80 induces an almost 90% release of histamine from mast cells. Thus, an appropriate amount of compound 48/80 has been used as a direct and convenient reagent to investigate the mechanisms of allergy and anaphylaxis (Allansmith et al., 1989). The murine mast cell is a good experimental model for the study of compound 48/80-induced histamine release.

Curcumin is a yellow dye in the crude drug “Turmeric” (Curcumae Rhizoma) from the rhizome of Curcuma longa L. (Zingiberaceae). Curcumin is known to have anti-tumor, anti-inflammatory, anti-oxidative, and anti-allergic effects...
Effects of curcumin on compound 48/80-induced mast cell activation

(Cui et al., 2006; Eybl et al., 2006; Kurup & Barrios, 2008). In addition, previous studies demonstrated that curcumin had an inhibitory effect on histamine release from mast cells triggered by IgE, calcium ionophore A23187, or concanavalin A (Suzuki et al., 2005; Lee et al., 2008). However, there are no reports to date concerning the suppressive effect of curcumin on compound 48/80-induced anaphylactoid response.

In this study, we evaluated the effect of curcumin on the passive cutaneous anaphylactoid response and compound 48/80-induced histamine release from mast cells. In addition, the amount of calcium uptake and intracellular cAMP was determined to clarify the mechanism by which curcumin inhibited histamine release from mast cells.

Materials and Methods

Materials

Curcumin, compound 48/80, disodium cromoglycate (DSCG), bovine serum albumin (BSA), and HEPES were purchased from Sigma Chemical Co. (St. Louis, MO, USA). Percoll solution was purchased from Pharmacia (Uppsala, Sweden). For all in vitro experiments, curcumin was dissolved in dimethylsulfoxide (DMSO) and freshly diluted in HEPES-Tyrode buffer (136 mM NaCl, 5 mM KCl, 2 mM CaCl2, 11 mM NaHCO3, 0.6 mM NaH2PO4, 2.75 mM MgCl2, 5.4 mM HEPES, 1.0 mg/mL BSA, 1.0 mg/mL glucose, 0.1 mg/mL heparin, pH 7.4) before use.

Experimental animals

Male Sprague-Dawley rats (8 weeks old, 230~280 g) were purchased from Damool Science (Daejeon, Korea). Animals were housed 3~5 per cages in laminar air-flow cabinets maintained at 22±1°C and a relative humidity of 55±10% throughout the study. The Animal Research Committee of Chonbuk National University approved the animal study in accordance with the guidelines of the National Institutes of Health (NIH publication #85-23, 1985).

Passive cutaneous anaphylactoid response in rats

Curcumin (10, 50, 100 mg/kg body weight) was orally administered to each rat 1 hour before the injection of compound 48/80, which was injected intradermally (0.25 μg/50 μL) into the dorsal skin. Evans blue solution (1%) was intravenously injected into the penile vein of each rat and 30 minutes after the injection, the rats were sacrificed. Tissue sections around the intradermal injection site were excised and weighed, followed by extraction of extravasated Evans blue dye by incubation of biopsies in 1 mL formamide at 55°C for 24 hours. Absorbance was measured at 620 nm with a spectrophotometer (Spectra MAX PLUS, Molecular Devices, CA, USA), and tissue Evans blue concentrations quantified by interpolation on a standard curve of dye concentrations in the range of 0.01 to 30 μg/mL.

Preparation of rat peritoneal mast cells (RPMCs)

RPMCs were isolated as previously described (Cochrane & Douglas, 1974). In brief, rats were anesthetized with ether, injected with 10 mL of calcium-free HEPES-Tyrode buffer into the peritoneal cavity, and the abdomen gently massaged for approximately 90 seconds. The peritoneal cavity was opened, and the fluid aspirated using a Pasteur pipette. RPMCs were purified using a Percoll density gradient as described in detail elsewhere (Hachisuka et al., 1988). RPMC preparation was approximately 95% pure as assessed by toluidine blue staining and at least 98% of these cells were viable as assessed by trypan blue exclusion. Purified RPMCs (1×10^6 cells/mL) were resuspended in HEPES-Tyrode buffer.

RPMC viability assay

To test the viability of RPMCs, the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetric assay was performed as previously described (Yoshimura et al., 2004). Briefly, RPMCs (2×10^5 cells/well) were incubated with various concentrations (10~100 μM) of curcumin at 37°C for 2 hours. After addition of MTT (100 μg in 100 μL saline), RPMCs were incubated at 37°C for 1 hour. Crystallized MTT was dissolved and the absorbance measured at 570 nm with a spectrophotometer (Spectra MAX PLUS, Molecular Devices, CA, USA).

Histamine assay

RPMC suspensions (2×10^5 cells in 200 μL) were pre-incubated with curcumin (10~50 μM) at 37°C for 5 minutes and then incubated with compound 48/80 (0.25 μg/mL) for 15 minutes. Following centrifugation at 150×g for 10 minutes at 4°C, the amount of histamine in the supernatant was determined by the radioenzymatic method (Harvima et al., 1988). The inhibition percentage of histamine release was calculated using the following formula: % inhibition = [(histamine release without curcumin-histamine release with curcumin)/histamine release without curcumin]×100.
Measurement of $^{45}$Ca uptake

The calcium uptake of mast cells was measured according to the method described by Choi et al. (Choi et al., 2006a). Purified RPMCs were resuspended in HEPES-Tyrode buffer containing $^{45}$Ca (1.5 mCi/mL; 1 Ci=3.7×10$^{10}$ becquerels; PerkinElmer Life Sciences, MA, USA), and incubated at 4°C for 10 minutes. Mast cell suspensions were preincubated with curcumin (10−50 μM) at 37°C for 5 minutes and then incubated with compound 48/80 (0.25 μg/mL) at 37°C for 15 minutes. The reaction was stopped by the addition of 1 mM lanthanum chloride. The samples were centrifuged 3 times at 150×g for 10 minutes at 4°C, and then RPMCs were lysed with 10% Triton X-100 and vigorous shaken. Radioactivity of the solution was measured in a scintillation β-counter (Liquid Scintillation Analyzer, A Canberra Company, Australia).

cAMP assay

The cyclic adenosine-3', 5' monophosphate (cAMP) level was measured by the method described by Holmegaard (Holmegaard, 1982). In brief, an RPMC suspension was added to an equivalent volume (200 μL) of prewarmed buffer containing the drug in an Eppendorf tube. The reaction was allowed to proceed for discrete time intervals, terminated by centrifugation at 150×g for 10 minutes at 4°C, and then each sample was added to 250 μL of 50 mM sodium acetate buffer (pH 6.2) under vigorous vortexing, followed by snap freezing in liquid nitrogen. Frozen samples were thawed and vortexed and the debris sedimented by centrifugation at 1,200×g for 10 minutes at 4°C. The cAMP level in the supernatant was determined by radioimmunoassay using a Rianen assay system (PerkinElmer Life Sciences, Boston, MA, USA).

Statistical analysis

The results obtained were expressed as mean±SEM for the number of experiments. Statistical evaluation of the results was performed using one-way ANOVA, followed by Duncan’s multiple range tests. Results with P<0.05 were considered statistically significant.

Results

Curcumin attenuates the passive cutaneous anaphylactoid response

To confirm the anti-anaphylactoid effect of curcumin, we used an in vivo model induced by compound 48/80. It has been previously demonstrated that the intradermal injection of compound 48/80 into the dorsal skin of rats provokes an increase of mast cell-dependent vascular permeability documented by Evans blue extravasation (Choi et al., 2006b). As shown in Table 1, oral administration of curcumin dose-dependently reduced the vascular permeability changes triggered by compound 48/80. Likewise, DSCG (a reference drug) exhibited a significant inhibition at a dose of 100 mg/kg.

Table 1. Inhibitory effect of curcumin on compound 48/80-induced passive cutaneous anaphylactoid response

| Treatment (mg/kg BW) | Compound 48/80 (0.25 μg/site) | Amount of Evans blue (μg/g) | Inhibition (%) * |
|----------------------|-------------------------------|----------------------------|-----------------|
| Curcumin 0           | —                             | 47.25±3.8                  | —               |
| 0                    | +                             | 261.59±14.32               | —               |
| 10                   | +                             | 238.13±11.90               | 08.96 †         |
| 50                   | +                             | 164.56±12.74               | 37.09 †         |
| 100                  | +                             | 142.81±06.49               | 45.41 †         |

DSCG 100 + 127.35±08.67 51.32 †

Curcumin or DSCG was orally administrated at 1 hour before compound 48/80 injection. Twenty micro liters of compound 48/80 (0.25 μg/site) were intradermally injected into the shaved flank of Sprague-Dawley rats. Each amount of Evans blue represents the mean±S.E.M. of five independent experiments. *Inhibition (%) = [(amount of Evans blue without curcumin - amount of Evans blue with curcumin)/amount of Evans blue without curcumin]×100. †P<0.05, significantly different from the control value.

Fig. 1. Effect of curcumin on rat peritoneal mast cell (RPMC) viability. RPMCs were treated with the various concentrations of curcumin for 2 hours. RPMC viability was determined by MTT assay and the percentage of viability was calculated as a ratio of $A_{570}$ of control cells (treated with HEPES-Tyrode buffered solution). Each data value represents the mean±S.E.M. of five independent experiments.
Curcumin has no cytotoxicity on RPMCs at a dose of 10\textasciitilde50 \mu M

MTT conversion assay was used to determine the viability of RPMCs exposed to curcumin. Viable cells were almost 100\% after exposure to 10\textasciitilde50 \mu M of curcumin for 2 hours. However, at 100 \mu M, curcumin had cytotoxic effects on RPMCs (Fig. 1). Thus, we performed in vitro experiments at 10\textasciitilde50 \mu M of curcumin.

Curcumin inhibits compound 48/80-induced RPMC degranulation

To investigate how curcumin inhibited the passive cutaneous anaphylactoid response, we evaluated the effect of curcumin on compound 48/80-induced mast cell activation. The effect of curcumin on compound 48/80-induced histamine release from RPMCs is shown in Fig. 3. The histamine release from compound 48/80-treated RPMCs was reduced in a dose-dependent manner by curcumin (58 and 80\% inhibition at 25 and 50 \mu M, respectively).

Curcumin reduces compound 48/80-induced calcium uptake into RPMCs

It is well established that an increase in calcium uptake of RPMCs contributes to the release of histamine (Akagi et al., 1994). Treatment with curcumin alone showed no change in calcium uptake. However, calcium uptake was greatly increased by stimulation of RPMCs with compound 48/80. The compound 48/80-induced calcium uptake was inhibited in a concentration-dependent manner by curcumin (Fig. 4).

Fig. 2. Inverted light micrographs of rat peritoneal mast cell (RPMC, arrows). (A) The normal RPMC in HEPES-Tyrode buffered solution. (B) The Degranulated RPMC after the addition of compound 48/80. (C) The RPMCs observed within 10 minutes after the addition of curcumin (50 \mu M) show similar findings as seen in Fig. 2A. (D) The RPMCs pretreated with curcumin observed within 10 minutes after the addition of compound 48/80, show similar findings as seen in Fig. 2C. Bars=10 \mu m.
Curcumin increases intracellular cAMP level in RPMCs

The cAMP pathway is believed to be critical for the regulation of mast cell activation. An increase of cAMP is known to precede the inhibition of histamine release from mast cells activated by compound 48/80 (Kaliner & Austen, 1974). To investigate the mechanism of curcumin on the reduction of histamine release from RPMCs stimulated by compound 48/80, we assessed intracellular cAMP levels. Treatment of curcumin alone increased cAMP levels in a dose-dependent manner. Treatment of RPMCs with compound 48/80 showed a significant decrease in cAMP levels as compared to those treated with buffer alone (49.05±3.75% of normal value). However, pretreatment with curcumin blocked the compound 48/80-induced reduction of cAMP in RPMCs (Fig. 5).

Discussion

As part of our studies on bioactive constituents from natural medicines, we previously reported various inhibitors against mast cell degranulation and histamine release induced by compound 48/80 (Choi et al., 2006a; 2006b). In this study, curcumin inhibited compound 48/80-induced systemic anaphylaxis and anti-DNP IgE-mediated PCA. These results indicate that nonspecific and specific mast cell-dependent allergic reactions were significantly inhibited by curcumin. It is well-recognized that compound 48/80 can induce a mast cell-dependent, non-specific anaphylactoid reaction. The mechanism of anaphylactoid response triggered by compound 48/80 is considered to be due to the massive release of vasoactive amines, such as histamine, from mast cells and...
basophils (Allansmith et al., 1989). As noted, histamine is a
typical mediator that causes various pathophysiologic events
in acute allergic reactions (Galli, 1993). Thus, it is postulated
that curcumin inhibits mast cell-mediated anaphylactoid
responses by suppressing histamine release from RPMCs.
Compound 48/80 is known to activate mast cell secretory
processes by increasing the rate of GTPγS binding to
G-proteins (Palomäki & Laitinen, 2006); in turn, the activation
of G-proteins can trigger intracellular signaling events such as
activation of phospholipase, protein kinase C (PKC) and Ca²⁺
signaling which ultimately results in the release of histamine
from these cells. Inositol 1,4,5-triphosphate then causes
the movement of Ca²⁺ form the endoplasmic reticulum,
triggering store-operated Ca²⁺ entry through specialized Ca²⁺
release-activated calcium channels (Turner & Kinet, 1999).
Degranulation of mast cells is involved in the synergistic
activation of PKC and the increase in intracellular calcium
concentration. The increase in intracellular Ca²⁺ induces the
movement of granules to the plasma membrane followed by
the degranulation of mast cells or basophils and activated
formation of inflammatory mediators such as prostaglandins
and leukotrienes. Compound 48/80 also stimulates histamine
release from RPMCs in both the presence and absence of
extracellular calcium. The present study demonstrates that
curcumin potently suppressed histamine release probably
through the inhibition of the degranulation process following
a rise in intracellular Ca²⁺ levels, in accordance with previous
reports (Matsuda et al., 2004; Suzuki et al., 2005; Nugroho et
al., 2009).

The cAMP pathway is supposed to be critical to the
activation of mast cells. It has been reported that agents that
induce the elevation of intracellular cAMP levels can attenuate
the stimulated release of mediators from mast cells (Weston
& Peachell, 1998). Moreover, several studies have shown an
algorithm between cAMP and calcium uptake in RPMCs.
In general, increased cAMP inhibits superoxide anion
generation via cAMP-dependent protein phosphorylation
in RPMCs stimulated by compound 48/80 (Fukuishi et
al., 1997). Decreased superoxide anion, as well as cAMP,
impedes inositol 1,4,5-triphosphate or GTP-induced calcium
release from the endoplasmic reticulum (Yoshii et al., 1988;
Akagi et al., 1994). Accordingly, calcium-filling state in the
endoplasmic reticulum blocks a calcium influx into RPMCs,
which leads to a reduction in the free intracellular calcium
content (Hoth & Penner, 1993). Consequently, decreased
intracellular calcium prevents histamine release from RPMCs
(Yoshii et al., 1988; Akagi et al., 1994). Interestingly, treatment
with curcumin significantly increases the cAMP level beyond
the basal level. Although the mechanism of curcumin-
induced cAMP production has not been elucidated, curcumin
may activate adenylate cyclase directly or indirectly, otherwise
inhibiting cAMP phosphodiesterase. In addition, curcumin
prevents compound 48/80-induced cAMP reduction and
calcium uptake of RPMCs in a dose-dependent fashion.
According to these observations, the inhibitory mechanism of
curcumin on histamine release from compound 48/80-treated
RPMCs may be due to an increase of intracellular cAMP.
Based upon this information, we speculate that the curcumin-
induced increase in cAMP inhibits calcium uptake into
RPMCs via the cascade of intracellular events described
previously and the subsequent decrease of intracellular
calcium content hinders histamine release from RPMCs.
In summary, the present data demonstrate that curcumin
suppresses both the passive cutaneous anaphylactoid
response and compound 48/80-induced mast cell activation.
This is the first study to evaluate the effect of curcumin on
the anaphylactoid reaction induced by compound 48/80.
Although there are a few differences among the experimental
conditions in studies concerning anti-allergic activities of
curcumin, our results confirm those of Suzuki and co-workers
and Lee and co-workers (Suzuki et al., 2005; Lee et al., 2008).
It is well known that reactive species (ROS) are intimately
relevant to the induction of inflammation. The ROS generated
in macrophages may produce prostaglandins, nitric oxide,
and cytokines, leading to the development of inflammation
(Haddad et al., 2001). Curcumin was reported to depress the
release of ROS from macrophages (Joe & Lokesh, 1994),
inhibit the release of histamine from RPMCs (Suzuki et al.,
2005), and the release of TNF-α, and IL-4 from RBL-2H3
cells (Matsuda et al., 2004; Lee et al., 2008). These findings
indicate that curcumin is closely associated with anti-allergic
activities (Kurup & Barrios, 2008). The anti-allergic and anti-
obxidative activities of curcumin and related compounds, such
as glycosides and bis-demethoxy analogs, have currently been
investigated by Suzuki et al. (Suzuki et al., 2005). Their results
suggest that most of the compounds develop anti-allergic
activities through mechanisms related to both anti-oxidative
and non anti-oxidation activities. In conclusions, curcumin
may have beneficial effects in the prevention or treatment of
mast cell-mediated allergic diseases. The detailed mechanisms
of action of curcumin need to be studied further.
Acknowledgements

This work was supported by a Korea Research Foundation Grant funded by the Korean Government (KRF-2008-313-E00014).

References

Akagi M, Katakuse Y, Fukuishi N, Kan T, Akagi R. (1994). Superoxide anion-induced histamine release from rat peritoneal mast cells. Biol Pharm Bull 17: 732-734

Allansmith MR, Baird RS, Ross RN, Barney NP, Bloch KJ. (1989). Ocular anaphylaxis induced in the rat by topical application of compound 48/80. Dose response and time course study. Acta Ophthalmol Suppl 192: 145-153

Choi YH, Yan GH, Chai OH, et al. (2006a). Inhibition of anaphylaxis-like reaction and mast cell activation by water extract from the fruiting body of Phellinus linteus. Biol Pharm Bull 29: 1360-1365

Choi YH, Yan GH, Chai OH, et al. (2006b). Inhibitory effects of Agaricus blazei on mast cell-mediated anaphylaxis-like reactions. Biol Pharm Bull 29: 1366-1371

Cochrane DE, Douglas WW. (1974). Calcium-induced extrusion of secretory granules (exocytosis) in mast cells exposed to 48-80 or the ionophores A-23187 and X-537A. Proc Natl Acad Sci USA 71: 408-412

Cui SX, Qu XJ, Xie YY, et al. (2006). Curcumin inhibits telomerase activity in human cancer cell lines. Int J Mol Med 18: 227-231

Ennis M, Pearce FL, Weston PM. (1980). Some studies on the release of histamine from mast cells stimulated with polylysine. Br J Pharmacol 70: 329-334

Eybl V, Kotyzova D, Koutensky J. (2006). Comparative study of natural antioxidants - curcumin, resveratrol and melatonin - in cadmium-induced oxidative damage in mice. Toxicology 225: 150-156

Fukuishi N, Sakaguchi M, Matsuura S, Nakagawa C, Akagi R, Akagi M. (1997). The mechanisms of compound 48/80-induced superoxide generation mediated by A-kinase in rat peritoneal mast cells. Biochem Mol Med 61: 107-113

Galli SJ. (1993). New concepts about the mast cell. N Engl J Med 328: 257-265

Hachisuka H, Nomura H, Sakamoto F, Mori O, Okubo K, Sasai Y. (1988). Effect of antianaphylactic agents on substance-P induced histamine release from rat peritoneal mast cells. Arch Dermatol Res 280: 158-162

Haddad JJ, Safieh-Garabedian B, Saade NE, et al. (2001). Chemioxyexcitation (delta pO2/ROS)-dependent release of IL-1 beta, IL-6 and TNF-alpha: evidence of cytokines as oxygen-sensitive mediators in the alveolar epithelium. Cytokine 13:138-147

Harvima RJ, Harvima IT, Fräki JE. (1988) Optimization of histamine radio enzyme assay with purified histamine-N-methyltransferase. Clin Chim Acta 171: 247-256

Holmegaard SN. (1982). Measurement of cyclic AMP in clinical investigations. Acta Endocrinol Suppl (Copenh) 249: 1-47

Hoth M, Penner R. (1993). Calcium release-activated calcium current in rat mast cells. J Physiol 465: 359-386

Joe B, Lokesh BR. (1994). Role of capsaicin, curcumin and dietary n-3 fatty acids in lowering the generation of reactive oxygen species in rat peritoneal macrophages. Biochim Biophys Acta 1224: 255-263

Kalesnikoff J, Galli SJ. (2008). New developments in mast cell biology. Nat Immunol 9: 1215-1223

Kaliner M, Austen KE. (1974). Cyclic AMP, ATP, and reversed anaphylactic histamine release from rat mast cells. J Immunol 112: 664-674

Kurup VP, Barrios CS. (2008). Immunomodulatory effects of curcumin in allergy. Mol Nutr Food Res 52: 1031-1039

Lee JH, Kim JW, Ko NY, et al. (2008). Curcumin, a constituent of curry, suppresses IgE-mediated allergic response and mast cell activation at the level of Syk. J Allergy Clin Immunol 121: 1225-1231

Matsuda H, Tewtrakul S, Morikawa T, Nakamura A, Yoshikawa M. (2004). Anti-allergic principles from Thai zedoary: structural requirements of curcuminoids for inhibition of degranulation and effect on the release of TNF-α and IL-4 in RBL-23 cells. Bioorg Med Chem 12: 5891-5898

Nugroho AE, Ikawati Z, Sardijiman, Maeyama K. (2009). Effects of benzylidencyclopentanone analogues of curcumin on histamine release from mast cells. Biol Pharm Bull 32: 842-849

Palomäki VA, Laitinen JT. (2006). The basic secretagogue compound 48/80 activates G proteins indirectly via stimulation of phospholipase D-lysophosphatidic acid receptor axis and 5-HT1A receptors in rat brain sections. Br J Pharmacol 147: 596-606

Petersen LJ, Mosbech H, Skov PS. (1996). Allergen-induced
Effects of curcumin on compound 48/80-induced mast cell activation

histamine release in intact human skin in vivo assessed by skin microdialysis technique: characterization of factors influencing histamine releasability. J Allergy Clin Immunol 97: 672-679

Suzuki M, Nakamura T, Iyoki S, et al. (2005). Elucidation of anti-allergic activities of curcumin-related compounds with a special reference to their anti-oxidative activities. Biol Pharm Bull 28: 1438-1443

Tasaka K, Mio M, Okamoto M. (1986). Intracellular calcium release induced by histamine releasers and its inhibition by some antiallergic drugs. Ann Allergy 56: 464-469

Turner H, Kinet JP. (1999). Signalling through the high-affinity IgE receptor Fc epsilonRI. Nature 402s(6760 Suppl): B24-30

Weston MC, Peachell PT. (1998). Regulation of human mast cell and basophil function by cAMP. Gen Pharmacol 31: 715-719

Yoshii N, Mio M, Tasaka K. (1988). Ca uptake and Ca releasing properties of the endoplasmic reticulum in rat peritoneal mast cells. Immunopharmacology 16: 107-113

Yoshimura T, Hamaguchi E, Usami E, et al. (2004). Increased in vitro release of interferon-gamma from ampicillin-stimulated peripheral blood mononuclear cells in Stevens-Johnson syndrome. Biol Pharm Bull 27: 929-931